COVI-DROPS

BIOLOGICAL3 trials

Sponsors

Sorrento Therapeutics, Inc.

Conditions

COVID-19Covid19

Phase 2

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)

TerminatedNCT04900428

Sorrento Therapeutics, Inc.Covid19

Start: 2021-07-16End: 2022-05-06Updated: 2023-01-30

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)

CompletedNCT04906694

Sorrento Therapeutics, Inc.Covid19

Start: 2021-11-16End: 2022-01-13Updated: 2022-02-03

Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection

WithdrawnNCT05074394

Sorrento Therapeutics, Inc.COVID-19

Start: 2021-11-30End: 2023-01-31Updated: 2022-02-03